Patent directory · USPTO A61K / A61P
Patents matching “mab”
86 pharma patents match "mab" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 86 pharmaceutical patents matching "mab" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
NO 2026007
Serplulimab
granted -
US 12391765
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
granted -
US 12364661
Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
granted -
WO 2025147499
LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE
granted -
WO 2025137347
FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION
granted -
US 12297186
Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
granted -
US 12246064
Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
granted -
US 12240914
Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof
granted -
US 12133884
Methods of substituting pathogenic amino acids using programmable base editor systems
granted -
US 12129307
HER-2 binding antibodies
granted -
US 12084504
Anti-MET antibodies and uses thereof
granted -
US 12018074
Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
granted -
CN 117980330
Homodimeric peptides and antibodies comprising same
granted -
US 11904017
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
granted -
US 11896617
Polynucleotides encoding rituximab-resistant chimeric antigen receptors
granted -
US 11884731
Vedolizumab for the treatment of fistulizing Crohn's disease
granted -
US 11851671
Programmable assembly of virus composites for receptor-targeted gene delivery
granted -
US 11834507
Anti-MET agonist antibody for use in the treatment of colorectal cancer
granted -
US 11702478
Agonistic CD40 antibodies
granted -
US 11647776
Extract, consumable product and method for enriching bioactive metabolite in an extract
granted -
US 11613586
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
granted -
US 11491231
Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the assembly of morphologically-tunable soft materials
granted -
US 11464869
Non-adult human dosing of brentuximab vedotin
granted -
US 11439585
Programmable pharmaceutical compositions for chrono drug release
granted